表紙
市場調查報告書

多發血管性肉芽腫症 (韋格納肉芽腫) :開發中產品分析

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 409618
出版日期 內容資訊 英文 99 Pages
訂單完成後即時交付
價格
多發血管性肉芽腫症 (韋格納肉芽腫) :開發中產品分析 Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 99 Pages
簡介

所謂多發血管性肉芽腫症 (韋格納肉芽腫)是會引起血管發炎的難治之症之一,特徵是由於血管發炎妨礙了血液流入各個人體組織。主要的症狀·前兆有持續性的鼻涕和鼻血,耳朵感染疾病,咳嗽,胸部疼痛,皮膚爛,發熱等。主要的易罹病素質中包含年齡等。主要的治療方法則有免疫抑制治療和皮質類固醇劑等。

本報告提供多發血管性肉芽腫症 (韋格納肉芽腫的)治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供你涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

多發血管性肉芽腫症 (韋格納肉芽腫) 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

開發治療藥的企業

  • Bionovis SA
  • Bristol-Myers Squibb Company
  • ChemoCentryx Inc
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • GlaxoSmithKline Plc
  • Iltoo Pharma
  • Panacea Biotec Ltd
  • Sandoz International GmbH
  • The International Biotechnology Center (IBC) Generium

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11959IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H1 2020, provides an overview of the Granulomatosis with Polyangiitis (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 2, 1 and 4 respectively.

Granulomatosis with Polyangiitis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Overview
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Companies Involved in Therapeutics Development
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • ChemoCentryx Inc
  • Generium
  • GlaxoSmithKline Plc
  • Humanigen Inc
  • iBio Inc
  • InflaRx NV
  • Insmed Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Pharmapraxis
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drug Profiles
  • abatacept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • avacopan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HGEN-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IFX-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INS-1007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mepolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biobetter - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 30, 2020: The CHMP recommended extensions of indication for MabThera
  • Oct 09, 2019: Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment
  • Sep 30, 2019: Roche's Rituxan secures approval for first paediatric indication
  • Jun 12, 2019: FDA grants priority review to Genentech's Rituxan (Rituximab) in children with two rare blood vessel disorders
  • May 16, 2019: GSK presents Nucala at ATS 2019
  • Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
  • Dec 12, 2017: GSK Achieves Approval for Nucala (mepolizumab) for the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) for Adults in the US
  • Jun 28, 2017: GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
  • Mar 25, 2014: NICE says yes to new treatment for rare autoimmune disease in final guidance
  • Feb 14, 2014: GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis
  • Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera
  • Apr 19, 2011: Genentech Receives FDA Approval For Rituxan Plus Steroid For Use In Severe Forms Of Vasculitis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Biogen Inc, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by ChemoCentryx Inc, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Generium, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Humanigen Inc, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by iBio Inc, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by InflaRx NV, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Insmed Inc, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Pharmapraxis, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects, H1 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020